Natural killer and natural killer-like T cell lymphomas represent a rare type of non-Hodgkin's lymphoma originally described to involve the upper aerodigestive tract. This malignancy has been increasingly observed in other extranodal sites, particularly in the skin. Patients with cutaneous natural killer cell lymphoma generally have a poor prognosis; however, the etiology and the underlying molecular pathogenesis remain unclear. This study aimed to investigate comprehensively genomic changes in blastic natural killer and extranodal natural killer-like T cell lymphoma with cutaneous involvement. Comparative genomic hybridization showed chromosome imbalances in six of eight cases studied (75%). The mean number of chromosome imbalances per sample was 2.1871.63 with similar number of gains (1.1871.17) and losses (1.0071.34). The most frequent DNA copy number changes observed were losses of 9/9p (83%), followed by loss of 13q and gain of 7 (67%). Similar patterns of chromosome imbalances were observed in both blastic natural killer and cutaneous natural killer-like T cell lymphomas. Loss of the RB1 gene at 13q14.2 was detected in one blastic natural killer cell lymphoma with 13q loss using a gene dosage assay, and in one cutaneous natural killer-like T cell lymphoma without 13q loss using £uorescent in situ hybridization. Genomic microarray analysis identi¢ed oncogene copy number gains of PAK1 and JUNB in three of four cases studied, and gains of RAF1, CTSB, FGFR1, and BCR in two cases. Real-time polymerase chain reaction detected ampli¢cation of CTSB and RAF1 in four of ¢ve cases analyzed, JUNB and MYCN in three cases, and REL and YES1 in two cases, respectively. In conjunction with this study, an extensive literature search for the published G-banded karyotypes of four subsets of natural killer cell lymphomas was conducted, which showed a nonrandom pattern of multiple chromosome aberrations. These results reveal consistent genetic alterations in cutaneous natural killer cell lymphomas, and provide a basis for further investigation of molecular pathogenesis in this malignancy.
Natural killer and natural killer-like T cell lymphomas represent a rare type of non-Hodgkin's lymphoma originally described to involve the upper aerodigestive tract. This malignancy has been increasingly observed in other extranodal sites, particularly in the skin. Patients with cutaneous natural killer cell lymphoma generally have a poor prognosis; however, the etiology and the underlying molecular pathogenesis remain unclear. This study aimed to investigate comprehensively genomic changes in blastic natural killer and extranodal natural killer-like T cell lymphoma with cutaneous involvement. Comparative genomic hybridization showed chromosome imbalances in six of eight cases studied (75%). The mean number of chromosome imbalances per sample was 2.1871.63 with similar number of gains (1.1871.17) and losses (1.0071.34). The most frequent DNA copy number changes observed were losses of 9/9p (83%), followed by loss of 13q and gain of 7 (67%). Similar patterns of chromosome imbalances were observed in both blastic natural killer and cutaneous natural killer-like T cell lymphomas. Loss of the RB1 gene at 13q14.2 was detected in one blastic natural killer cell lymphoma with 13q loss using a gene dosage assay, and in one cutaneous natural killer-like T cell lymphoma without 13q loss using £uorescent in situ hybridization. Genomic microarray analysis identi¢ed oncogene copy number gains of PAK1 and JUNB in three of four cases studied, and gains of RAF1, CTSB, FGFR1, and BCR in two cases. Real-time polymerase chain reaction detected ampli¢cation of CTSB and RAF1 in four of ¢ve cases analyzed, JUNB and MYCN in three cases, and REL and YES1 in two cases, respectively. In conjunction with this study, an extensive literature search for the published G-banded karyotypes of four subsets of natural killer cell lymphomas was conducted, which showed a nonrandom pattern of multiple chromosome aberrations. These results reveal consistent genetic alterations in cutaneous natural killer cell lymphomas, and provide a basis for further investigation of molecular pathogenesis in this malignancy. Key words: blastic natural killer cell lymphoma/chromosome imbalances/cutaneous natural killer-like T cell lymphoma/karyotype/oncogenes/RB1. J Invest Dermatol 121: 618^627, 2003 N atural killer and natural killer-like T cell lymphomas represent a rare type of non-Hodgkin's lymphoma that was originally reported to involve the upper aerodigestive tract Cheung et al, 1998) . This malignancy most frequently occurs in East Asia and Central and South America (Arber et al, 1993; Ja¡e et al, 1996; Cheung et al, 1998; Chuang et al, 2000; Ko et al, 2000; Nagasawa et al, 2000) , and can be associated with Epstein^Barr virus (EBV) (Kanavaros et al, 1993; Chan et al, 1994; Tsang et al, 1994; Tao et al, 1995) . The tumor cells express the neural cell adhesion molecule, which is recognized by the CD56 antibody (Ng et al, 1987) , and is thought to be involved in cell to cell interactions, homing mechanisms, and tumor cell dissemination (Cunningham et al, 1987; Lanier et al, 1991) . Natural killer and natural killer-like T cell lymphomas in other extranodal sites have been increasingly reported in recent years (Chan et al, , 2001a , and about 30% of cases have cutaneous involvement, which is the most frequent site of involvement after the aerodigestive tract (Ansai et al, 1997; Savoia et al, 1997; Natkunam et al, 1999 Natkunam et al, , 2000 Cho et al, 2000; El Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001) . These extranodal lymphomas were classi¢ed by the Revised European American Lymphoma classi¢cation as extranodal natural killer-like T cell lymphoma, nasal type with a cytotoxic T cell phenotype (Harris et al, 1994; Chan et al, 2001a) . The World Health Organization classi¢cation includes a separate entity described as blastic natural killer cell lymphoma, identical to the entity of primary cutaneous CD4 þ , CD56 þ lymphoma (Dummer et al, 1996) , without the presence of T cell or myeloid lineage (Harris et al, 2000; Chan et al, 2001b) . More recent studies have suggested that CD4 þ , CD56 þ lymphoma, or blastic natural killer cell lymphoma may arise from transformed cells of the lymphoid-related plasmacytoid dendritic cell subset or type 2 dendritic cell (DC2) (Brody et al, 1995; DiGiuseppe et al, 1997; Kameoka et al, 1998; Petrella et al, 1999 Petrella et al, , 2002 Ginarte et al, 2000; Chaperot et al, 2001; Feuillard et al, 2002; Khoury et al, 2002) ; however, whether this malignancy really belongs to DC2 tumor and expresses killer cell inhibitory receptors, such as CD158a, CD158b, p70, p140-KIR3DL, and CD94/natural killerG2A or not remain debating (Bagot et al, 1998 (Bagot et al, , 2001 Nikolova et al, 2002) . Clinically, patients with cutaneous natural killer cell lymphomas usually present with widespread smooth-surfaced nodules and plaques with a characteristic violaceous color. The tumors have a predilection for the trunk but also involve the extremities, the head and neck, and central nervous system (Ansai et al, 1997; Savoia et al, 1997; Natkunam et al, 1999 Natkunam et al, , 2000 Cho et al, 2000; El Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Child et al, 2003) . Histologically, there is a bottom-heavy dermal in¢l-trate without signi¢cant epidermotropism (Child et al, 2003) . Angiocentricity and red cell extravasation are present together with numerous blast-like mononuclear cells (Ansai et al, 1997; Savoia et al, 1997; Natkunam et al, 1999 Natkunam et al, , 2000 Cho et al, 2000; El Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Siu et al, 2002; Child et al, 2003) . The prognosis of natural killer and natural killer-like T cell lymphomas is very poor (Ansai et al, 1997; Savoia et al, 1997; Natkunam et al, 1999 Natkunam et al, , 2000 Cho et al, 2000; El Shabrawi-Caelen et al, 2000; Mraz-Gernhard et al, 2001; Siu et al, 2002; Child et al, 2003) . Despite recent progress in de¢ning the immunopathologic features of this disease, the etiology and underlying molecular pathogenesis remain unclear. Previous cytogenetic studies have shown a variety of nonrandom chromosomal abnormalities in natural killer cell lymphomas (Fernandez et al, 1986; Bassan et al, 1988; Taniwaki et al, 1990; Hart et al, 1992; Oshimi et al, 1993; Gelb et al, 1994; Brody et al, 1995; Callet-Bauchu et al, 1997; Tien et al, 1997; Kameoka et al, 1998; Petrella et al, 1999; Wong et al, 1999; Zhang et al, 1999; Hamaguchi et al, 2001; Leroux et al, 2002) ; however, unlike nodal non-Hodgkin's lymphoma, no recurrent chromosome translocations have been identi¢ed in this malignancy.
Most malignancies accumulate a series of genetic events, including activation of oncogenes and loss of tumor suppressor genes, leading to a malignant phenotype. Comparative genomic hybridization (CGH) is a molecular cytogenetic technique used to identify chromosomal imbalances representing regions of gain and loss. Previous CGH studies have shown a variety of DNA copy number changes in nodal and extranodal lymphomas (Knuutila et al, 2000; Siu et al, 1999 Siu et al, , 2002 Ko et al, 2001) .We have identi¢ed consistent and distinctive patterns of chromosome imbalances in mycosis fungoides/Se Ł zary syndrome, primary cutaneous B cell lymphoma, and primary cutaneous CD30 þ anaplastic large cell lymphoma (CD30 þ anaplastic large cell lymphoma) (Mao et al, 2002a (Mao et al, ,b, 2003b . Genomic microarray is a novel genomic analysis technology used to screen rapidly for genomic imbalances in a tumor genome (Pinkel et al, 1998) . Previous studies have shown oncogene copy number changes in several epithelial cancers (Pinkel et al, 1998; Daigo et al, 2001; Hui et al, 2001 Hui et al, , 2002 .We have also detected gains and losses of various di¡erent oncogenes in mycosis fungoides/Se Ł zary syndrome, primary cutaneous B cell lymphoma and CD30
þ anaplastic large cell lymphoma using genomic microarray technique (Mao et al, 2002b (Mao et al, , 2003a . There are no data available, however, on cutaneous natural killer cell lymphomas.
To address the issues of whether there are consistent genomic changes in cutaneous natural killer cell lymphomas, we have investigated eight cases using CGH, genomic microarray and realtime polymerase chain reaction (real-time PCR). In addition, we have analyzed the RB1 gene in three cases with 13q loss and one case without 13q loss using gene polymorphism and gene dosage assays, and £uorescent in situ hybridization.We have then correlated these ¢ndings with the results of an extensive literature review.
MATERIALS AND METHODS
Samples The study was approved by St. Thomas' Hospital Research Ethics Committee. A total of 11 DNA samples from eight patients with cutaneous natural killer cell lymphomas were selected for this study based on clinico-pathologic features, immunophenotype, extensive staging investigations, and the results of T cell receptor (TCR)/immunoglobulin (IGH) gene analysis ( Table I) (Child et al, 2003) . This included four cases of blastic natural killer lymphoma with a germline con¢guration of the TCR gene, and four cases of extranodal natural killer-like T cell lymphoma with a clonal TCR gene rearrangement. Two patients (cases 3 and 5) had lymph node and bone marrow involvement, and case 3 also had nasal antrum involvement at presentation. Two other patients (cases 5 and 8) had leukemia. Immunophenotypic studies demonstrated that all eight cases studied were CD56 positive. In addition, case 3 had a clonal B cell population with a rearrangement of the IGH gene, a t(14;18) translocation, and BCL2 positive staining. Only case 4 was positive for EBV detected with in situ hybridization (Child et al, 2003) . This study was approved by the St Thomas' Hospital Research Ethics Committee for sampling (EC02/089).
CGH DNA was extracted from the skin lesions, peripheral blood mononuclear cells, lymph nodes, and bone marrow from the patients with cutaneous natural killer cell lymphomas using standard procedures. CGH was performed as previously described (Kallioniemi et al, 1994; Mao et al, 2001 Mao et al, , 2002a Mao et al, ,b, 2003b . At least 10 metaphases were captured and analyzed on a Leica DMRXA £uorescence microscope (Leica Mitroskopie und System, Solms, Germany) with a COHU chargedcoupled device camera using MacProbe 4.0 software (Perceptive Scienti¢c Instruments International Ltd, Chester, UK). The threshold set for gains corresponded to a mean hybridization ratio between tumor and normal of greater than 1.25:1, and losses of less than 0.75:1 (Fig 1) (Kallioniemi et al, 1994; Mao et al, 2001 Mao et al, , 2002a Mao et al, ,b, 2003a .
Analysis of the RB1 gene with molecular and £uorescent in situ hybridization assays To con¢rm CGH ¢ndings on 13q in this study, two blastic natural killer cell lymphomas (sample nos 1231 and 1683) and one cutaneous natural killer-like T cell lymphoma sample (no. 1733) with 13q loss were analyzed using gene polymorphism assay. In this experiment, 100 ng of tumor DNA was ampli¢ed with the £uorescently labeled primer sets for Rbi.2 (microsatellite) and RB1.20 (variable number tandem repeat, VNTR) (Onadim et al, 1992 (Onadim et al, , 1997 , and the PCR products were then analyzed for intragenic RB1 polymorphism using ALFexpress automatic sequencer (Amersham Biosciences, Bucks, UK).
To assess further the copy number loss of RB1 at a molecular level, a £uorescent dosage assay was conducted in sample 1231. Brie£y, 100 ng of tumor DNA was ampli¢ed with 32 pairs of £uorescently labeled primers, in 11 multiplex reactions, covering all exons with associated splice sites, the promoter region, 3 0 untranslated region and the poly(A) site of the entire RB1 gene (NCBI LocusLink, 2002) . The PCR products were analyzed using ALFexpress (Amersham Biosciences). The RB1 gene dosage was determined by the dosage quotient. The dosage quotient value between 0.76 and 1.28 was set as the level for disomy (normal gene dosage), whereas the value between 0.36 and 0.68 was regarded as monosomy (hemizygosity).
In addition, single-color £uorescent in situ hybridization was carried out on the available slide containing metaphase chromosomes and interphase nuclei from case 8 (sample 2634). Brie£y, SpectrumOrange labeled RB1 probe, LSI 13 (Vysis Inc., Downers Grov, Illinois), was applied to the patient slide, and codenatured on a hot block at 701C for 5 min, and hybridized at 371C overnight. Posthybridization washing and £uorescent image analysis were as described previously (Mao et al, 2001 (Mao et al, , 2002a (Mao et al, , 2003a .
Genomic microarray To de¢ne genomic imbalances, four cases of blastic natural killer cell lymphoma (nos 1, 2, 4, and 6) with noticeable chromosome imbalances detected by CGH were selected for genomic microarray analysis. This experiment was conducted as previously described (Pinkel et al, 1998; Daigo et al, 2001; Hui et al, 2001 Hui et al, , 2002 Mao et al, 2002b Mao et al, , 2003a . After probe labeling, hybridization and posthybridization washes, £uorescent images of the hybridized microarray chips, AmpliOnc I DNA array (Vysis Inc.), which contains 59 clones from 57 oncogenes (BCL2 and AR are represented by both 5 0 and 3 0 genomic clones) representing genomic regions that have been reported to be ampli¢ed in human tumors, were captured and analyzed using the GenoSensor Reader System (Vysis Inc.). The £uorescent ratio threshold for gains and losses of oncogene copy number were set according to our control experiments (Mao et al, 2002b (Mao et al, , 2003b . The measured £uorescent ratios of oncogenes on autosomes ranged from 0.8 to 1.2 with a mean ratio of 1 and SD of 0.2 in testing samples. The ratios on AR located at Xq11q12 were beyond 1.25 in normal female to male control sets due to the extra copy of X chromosome from normal female DNA, and below 0.75 in normal male to female control sets due to one copy of X chromosome from male DNA. Therefore a value of 170.2 was set as the level for disomy (normal gene copy number), whereas ratios greater than 1.25 were regarded as cut-o¡ for trisomy (gain of gene copy number), and ratios less than 0.75 as cut-o¡ for monosomy (loss of gene copy number) (Mao et al, 2002b (Mao et al, , 2003a .
Real time^PCR To validate further and clarify chromosome imbalances and genomic imbalances identi¢ed by CGH and genomic microarray in this study, four cases of blastic natural killer lymphoma (nos 1, 2, 4, and 6) and one cutaneous natural killer-like T cell lymphoma (case 3) showing noticeable genomic changes were analyzed using real-time PCR. A total of seven oncogenes (targets), namely MYNC, REL, RAF1, CTSB, YES1, BCL2, and JUNB, and two housekeeping genes, B2M and ALB (reference) were tested (MWG Biotech, High Point, North Caroline) ( Table II) . This experiment, based on the Taqman assay (Bieche et al, 1998) , was carried out using the ABI Prism 7700 Sequence Detector System (ABI/Perkin Elmer, Foster City, California) as previously reported (Mao et al, 2002b (Mao et al, ,c, 2003b . The parameter C T is de¢ned as the fractional cycle number at which the £uorescence generated by cleavage of the probe passes a ¢xed threshold above baseline. The target gene copy number is quanti¢ed by measuring C T and by using a standard curve to determine the starting copy number. The ratio of the target gene copy number to the reference gene copy number normalizes the amount and quality of genomic DNA. The ratio de¢ning the level of increased copy number of the target gene was termed as ''N'' and was determined as follows: N ¼ copy number of target gene/copy number of reference gene. An N-value greater than 2 was set for gene ampli¢cation (Mao et al, 2002b (Mao et al, , 2003a .
Literature review To compare our ¢ndings with previous published cytogenetic data, we have collated the G-banded karyotypes of peripheral 
T cell lymphoma/natural killer cell lymphoma, nonspeci¢c, blastic natural killer cell lymphoma (CD4 þ CD56 þ DC2), extranodal natural killer-like T cell lymphoma, nasal type (natural killer/TCL), and aggressive natural killer cell lymphoma/leukemia (aggressive natural killer cell lymphoma/ leukemia) through an extensive literature search (Fernandez et al, 1986; Koizumi et al, 1986; Bassan et al, 1988; Sheridan et al, 1988; Taniwaki et al, 1990; Hart et al, 1992; Sun et al, 1992 Sun et al, , 1993 Oshimi et al, 1993; Gelb et al, 1994; Brody et al, 1995; Shimodaira et al, 1995; Wong et al, 1995 Wong et al, , 1997 Wong et al, , 1999 Wong et al, , 2000 Callet-Bauchu et al, 1997; DiGiuseppe et al, 1997; Suzuki et al, 1997; Tien et al, 1997; Kameoka et al, 1998; Petrella et al, 1999; Zhang et al, 1999; Hamaguchi et al, 2001; Leroux et al, 2002 ; Mitelman Database of Chromosome Aberrations in Cancer, 2002). All chromosome aberrations were grouped into chromosomal losses and gains, and structural rearrangements.
RESULTS
CGH Of the eight cases (11 DNA samples) analyzed in this study, six showed chromosome imbalances (75%). Overall the mean number of chromosome imbalances per sample was 2.1871.63 with similar number of gains (1.1871.17) and losses (1.0071.34). The most frequent DNA copy number changes (minimum three cases) were losses of 9/9p (¢ve of six, 83%), followed by loss of 13q and gain of 7 (four of six, 67%) ( Table I ) (Figs 1^3). Less frequent chromosome imbalances (o 3 cases), including losses of 2q, 3p, and 12p, and gains of 4, 5q, 6p, 9q, 18, and 19 were also seen (Table I) (Fig 3) . A similar pattern of chromosome imbalances was present in both blastic natural killer and cutaneous natural killer-like T cell lymphomas. There was only one case (no. 3) from which multiple DNA samples were analyzed. This case showed intratumoral variation in the pattern of chromosome imbalances, namely, blood (1734) and lymph node (1802) revealing gain of 18, skin (1733) demonstrating losses of 3p, 9, and 13q, and bone marrow (1781) having a normal copy number ( Table I) .
RB1 assays All three samples (nos 1231, 1683, and 1733) analyzed using the two intragenic RB1 polymorphic markers, Rbi.2 microsatellite and RB1.20 VNTR, exhibited single alleles with these polymorphisms. In addition, sample 1231, which was further analyzed for all RB1 regions (including the promoter and the 3 0 untranslated region) using £uorescent dosage screening, showed hemizygosity across all regions of RB1 tested (dosage quotient value ranged from 0.32 to 0.63), indicating the presence of only one copy of the RB1 gene. Furthermore, £uorescent in situ hybridization analysis of sample 2634 revealed that 67% of cells had two copies of RB1, and 33% of cells showed only one copy of RB1 (Fig 4) .
Genomic microarray All four cases studied by genomic microarray showed genomic imbalances (100%). Oncogene copy number gains of PAK1 and JUNB were observed in three cases, and RAF1, CTSB, FGFR1, and BCR in two cases (Figs 5 and 6). There was broad concordance between the results of CGH and genomic microarray in two cases (Figs 3 and 6). Case 2 (sample 1683) revealed losses of 9 and ABL1 (9q34.1). Case 4 (sample 1860) had gains of 6p21p22 and MYB (6q22). These two methods also revealed discordant results in case 6, however, which showed loss of chromosome 9 by CGH without loss of ABL1 (9q34.1) by genomic microarray (Figs 3 and 6 ).
Real-time PCR Of the ¢ve cases analyzed by real-time PCR, four showed ampli¢cation of CTSB and RAF1 (80%), three had ampli¢cations of JUNB and MYCN (60%), and two revealed ampli¢cations of REL and YES1 (40%) ( Table III) . The pattern of oncogene ampli¢cation in both blastic natural killer and cutaneous natural killer-like T cell lymphomas was similar. The real-time PCR results were consistent with the CGH and genomic microarray ¢ndings in all these cases (Tables I and III; Figs 3 and 6). For example, case 2 showed ampli¢cations of RAF1, CTSB, and JUNB by both real-time PCR and genomic microarray. Case 3 revealed ampli¢cations of YES1 and BCL2 (18q21.3) by genomic microarray, and gain of 18 by CGH. Case 4 had real-time PCR and genomic microarray evidence of MYCN, REL, RAF1, CTSB, and JUNB ampli¢cation. Case 6 showed ampli¢cations of JUNB by both real-time PCR and genomic microarray. Discrepancies between these three techniques, however, were present in case 1, which showed ampli¢cations of RAF1 and CTSB by real-time PCR without corresponding chromosomal or oncogene gains by either CGH or genomic microarray (Tables I and III Table IV . Among these subsets of natural killer cell lymphomas, peripheral T cell lymphoma/natural killer cell lymphoma nonspeci¢c showed multiple aberrations a¡ecting each individual chromosome, and the most common chromosome changes (4 10 cases) were gains of chromosomes 3, 5, 7, X, losses of 9, 14, 6/6q, and 17/17p, and a translocation involving 6p and 6q (Table IV) . Similar chromosome abnormalities were Table II . A summary of the primers and the probes used in real-time PCR
Gene
Forward primer Reverse primer Probe
, natural killer/TCL and aggressive natural killer cell lymphoma/leukemia but with involvement of only a few chromosomes/chromosomal regions ( Table IV) . The most frequent chromosome aberrations observed in CD4 þ CD56 þ DC2 (45 cases) were losses of 5/5q, 9, 12/12p, 13/13q, and 15, and gain of 6/6q. In natural killer/ TCL the most common chromosome changes (45 cases) were losses of 2/2q, 6/6q, and Y, and gain of X. Whereas losses of 7 and 10/10p were frequently seen in aggressive natural killer cell lymphoma/leukemia (45 cases) ( Table IV) . Overall our CGH Figure 2 . Illustration of a CGH karyotype of case 2. This karyotype was produced by the analysis of 11 high-quality normal metaphase spreads hybridized with the patient's DNA mixed with equal amount of normal reference DNA, which showed losses of 2q35q37, 9, 13q12q34, and Yq, and gain of 7p. results, such as losses of 2q, 9, 12p, and 13q, and gain of 7 identi¢ed in both blastic natural killer and cutaneous natural killer-like T cell lymphomas ( Table I) (Fig 3) , were consistent with previously cytogenetic ¢ndings ( Table IV) .
DISCUSSION
Our comprehensive genomic studies of blastic natural killer and cutaneous natural killer-like T cell lymphoma presenting in the skin have identi¢ed consistent patterns of genetic alterations. CGH showed losses of 9/9p in 83% of cases, and loss of 13q and gain of 7 in 67% of cases. In addition, RB1 assays revealed loss of this tumor suppressor gene in one blastic natural killer cell lymphoma and in one cutaneous natural killer-like T cell lymphoma. Furthermore, genomic microarray demonstrated oncogene copy number gains of PAK1 and JUNB in three cases, and gains of RAF1, CTSB, FGFR1, and BCR in two cases. This was supported by real-time PCR, which detected ampli¢cation of CTSB, RAF1, MYCN, JUNB, REL, and YES1 in more than 40% of cases analyzed. There was a concordance between the results of these techniques, although some discrepancies were also noted, which are likely to be due to either the di¡erent sensitivity of the techniques or intratumoral heterogeneity. Our extensive literature review also revealed nonrandom chromosome aberrations in four subsets of natural killer cell lymphomas, including losses of 2/2q, 5/5q, 6/6q, 9, 12/12p, and 13/13q, and gain of 7 (see the references cited in Materials and Methods). Our ¢ndings suggest that these genomic alterations may be critical in the pathogenesis of both blastic natural killer and cutaneous natural killer-like T cell lymphomas.
There have been two reports describing genome-wide DNA copy number changes in natural killer cell lymphomas from the high incidence areas (Siu et al, 1999; Ko et al, 2001) . One study showed frequent losses of chromosomes 6q, 11q, 13q, and 17p, and gains of 1p, 6p, 11q, 12q, 17q, 19p, 20q , and Xq in Chinese patients with nasal natural killer cell lymphoma and aggressive natural killer cell lymphoma/leukemia (Siu et al, 1999) . Another study revealed frequent gains of 2q, 3q, 5q, 10q, 13q, 17q, and 21q, and losses of 1p, 6q, 12q, 13q, and 17p in Korean patients with nasal natural killer/TCL (Ko et al, 2001) . East Asia, however, is one of the areas with the highest rates of EBV infection in the world (de-The et al, 1975; Henle and Henle, 1980) . In addition, EBV nonrandomly integrates into the human genome, and the human chromosome integration sites of EBV include chromosome bands of 1p31, 1q31, 1q43, 2p22, 2q32, 3q13, 3q28, 4q13, 5p14, 5q12, 6q24, 7q31, and 11p15 (Lestou et al, 1993; Wuu et al, 1996) . Therefore, it is di⁄cult to exclude the possibility that these genetic changes detected in natural killer cell lymphomas are a result of EBV infection. In contrast, all the patients analyzed in this study came from the UK, a low incidence area for both EBV infection and natural killer cell lymphomas, and only one of eight patients studied was EBV positive. The most intriguing ¢ndings in this study were the identi¢cation using CGH of losses of chromosomes 9/9p and 13q, and gain of 7, which were present in both blastic natural killer and cutaneous natural killer-like T cell lymphomas. These results are consistent with the previous cytogenetic reports (see the references cited in Materials and Methods), suggesting that the disruptions of genes on these chromosomes may be associated with cutaneous natural killer cell lymphomas. In addition, these ¢ndings are distinct from our previous observations in mycosis fungoides/Se Ł zary syndrome, primary cutaneous B cell lymphoma and CD30
þ anaplastic large cell lymphoma (Mao et al, 2002a (Mao et al, ,b, 2003b , implicating di¡erent pathogenesis. In this study, one blastic natural killer cell lymphoma with 13q loss identi¢ed by CGH showed a deletion of the RB1 gene by using gene dosage assay. Interestingly, loss of RB1 was also present in 33% of cells from a patient with cutaneous natural killer-like T cell lymphoma without showing 13q loss. In this case CGH may have failed to detect 13q loss because the number of tumor cells with RB1 loss were below the detection capacity. Other studies have also shown RB1 deletion and loss of RB1 protein expression in blastic natural killer cell lymphoma and cell lines (Sakajiri et al, 2001) . Taken together these ¢ndings suggest that loss of RB1 may be a common event in the development of cutaneous natural killer cell lymphomas.
There have been few reports of oncogenic abnormalities in natural killer cell lymphomas in the literature. For example, one study detected KRAS (12p12.1) mutations in 25% of nasal natural killer cell lymphomas (Hoshida et al, 2002) . In this study, although loss of 12p was detected in two cases by CGH, no copy number change of KRAS was seen in these cases. In contrast, ampli¢cations of RAF1, CTSB, and JUNB were identi¢ed in over 40% of cases using genomic microarray and real-time PCR. In addition, our immunophenotypic studies showed expression of JUNB protein in two cases (Mao et al, 2003a) . The pattern of genomic imbalances in cutaneous natural killer cell lymphomas was also distinctive from that in primary cutaneous B cell lymphoma (Mao et al, 2002b) , further implying di¡erent genetic pathway involved. RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1) is a mitogen-activated protein kinase, which acts downstream of RAS, and is regulated by BCL2 and other apoptosis-related proteins (NCBI LocusLink, 2002) . CTSB encodes cathepsin B, a lysosomal cysteine protease that cleaves amyloid precursor protein and is involved in tumor invasion (NCBI LocusLink, 2002) . Previous studies have shown ampli¢cations of RAF1 and CTSB in esophageal and urinary bladder carcinomas, respectively (Hughes et al, 1998; Simon et al, 2001) . We have also identi¢ed ampli¢cations of these oncogenes in mycosis fungoides/Se Ł zary syndrome and CD30
þ anaplastic large cell lymphoma (Mao et al, 2003a,c) . Further functional studies are now required to assess the potential role of these oncogenic alterations in the pathogenesis of cutaneous natural killer cell lymphomas.
Intratumoral variation of the pattern of chromosome imbalances has been reported in multiple tumor samples from the individual patients as evidence of genetic heterogeneity (Jung et al, 1999) . In this study, such variation was seen in case 3. DNA samples from blood and lymph nodes showed gain of 18, and lymph nodes also had ampli¢cation of BCL2 by real-time PCR. In contrast, skin sample revealed losses of 3p, 9, and 13q. Whereas the bone marrow sample did not demonstrate chromosome imbalances. In addition, conventional cytogenetic analysis of bone marrow samples detected trisomies 3, 13, and 18 in small number of cells (data not shown). Interestingly identical Vg1 (TCR) and VH1 (IGH) clonal rearrangements were identi¢ed in all samples from skin, blood, lymph node, and bone marrow. This was further complicated by the detection of a t(14;18) translocation, in both skin and lymph node. The t(14;18) translocation is known to occur in the majority of follicular lymphomas and some di¡use large B cell lymphomas (Weiss et al, 1987) . The clinical and pathologic features in this case were in keeping with a blastic natural killer cell lymphoma, and B cell markers were negative but 10% of the neoplastic cells within the in¢ltrate were CD3, CD8, and TIA-1 positive (Child et al, 2003) . These results suggest the presence of a transformed extranodal natural killer-like T cell lymphoma with cytotoxic features (Child et al, 2003) . The presence of a clonal IGH gene rearrangement could be explained by an anomalous IGH gene rearrangement in a T cell lymphoma but this would not explain the detection of a t(14;18) translocation, although this can be detected at very low levels in healthy individuals (Limpens et al, 1995) . Previous studies have suggested that natural killer-like T cell lymphoma originate from a T cell lineage (Ng et al, 1987; Macon et al, 1996; Chan et al, 1997) . Our data suggest, however, that both T and B lineage malignant cells presenting in this cutaneous natural killerlike T cell lymphoma may result from the molecular defects occurring at the stage of common lymphoid progenitors with the capacity to develop into T and B cells (Kondo et al, 1997) ; this may represent a genuine composite lymphoma as three additional cases also showed coexistence of T and B cell lymphomas (data not shown). Further study is therefore appropriate to clarify this hypothesis.
In summary, we have identi¢ed a consistent pattern of genomic alterations in cutaneous natural killer cell lymphomas, and further studies are underway to characterize the candidate genes using comprehensive genomic and proteomic approaches. 
CD4
þ CD56 þ DC22, CD4 þ CD56 þ type 2 dendritic cell acute leukaemiablastic natural killer cell lymphoma.
